Andrew Poklepovic

4.3k total citations
129 papers, 2.7k citations indexed

About

Andrew Poklepovic is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Andrew Poklepovic has authored 129 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Molecular Biology, 57 papers in Oncology and 29 papers in Epidemiology. Recurrent topics in Andrew Poklepovic's work include Histone Deacetylase Inhibitors Research (28 papers), Autophagy in Disease and Therapy (25 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Andrew Poklepovic is often cited by papers focused on Histone Deacetylase Inhibitors Research (28 papers), Autophagy in Disease and Therapy (25 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Andrew Poklepovic collaborates with scholars based in United States, France and Canada. Andrew Poklepovic's co-authors include Paul Dent, Laurence Booth, Jane L. Roberts, Victoria Barghout, Érick Moyneur, Arun J. Sanyal, Steven Grant, John M. Kirkwood, Nichola Cruickshanks and John F. Hancock and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andrew Poklepovic

123 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Poklepovic United States	30	1.5k	917	716	363	331	129	2.7k
Clint Mitchell United States	30	1.6k 1.1×	846 0.9×	528 0.7×	234 0.6×	347 1.0×	43	2.5k
Tyler Lahusen United States	25	1.7k 1.2×	1.3k 1.4×	533 0.7×	184 0.5×	335 1.0×	35	3.2k
Alexandre Puissant France	31	2.0k 1.3×	454 0.5×	828 1.2×	264 0.7×	251 0.8×	59	3.1k
Hayato Hikita Japan	29	1.7k 1.1×	600 0.7×	1.4k 1.9×	492 1.4×	347 1.0×	133	3.6k
José Palacios Spain	26	1.5k 1.0×	870 0.9×	365 0.5×	142 0.4×	195 0.6×	58	2.9k
Janice M. Mehnert United States	25	1.0k 0.7×	1.5k 1.6×	941 1.3×	363 1.0×	101 0.3×	89	2.7k
Cheng Ean Chee Singapore	18	955 0.6×	465 0.5×	788 1.1×	146 0.4×	151 0.5×	73	1.9k
Alberto Ballestrero Italy	32	1.7k 1.2×	1.5k 1.6×	436 0.6×	711 2.0×	134 0.4×	164	4.0k
Ayesha N. Shajahan‐Haq United States	31	1.6k 1.0×	565 0.6×	471 0.7×	190 0.5×	1.0k 3.1×	70	2.9k
Henning Schulze‐Bergkamen Germany	31	1.8k 1.2×	995 1.1×	676 0.9×	468 1.3×	202 0.6×	70	3.2k

Countries citing papers authored by Andrew Poklepovic

Since Specialization

Citations

This map shows the geographic impact of Andrew Poklepovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Poklepovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Poklepovic more than expected).

Fields of papers citing papers by Andrew Poklepovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Poklepovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Poklepovic. The network helps show where Andrew Poklepovic may publish in the future.

Co-authorship network of co-authors of Andrew Poklepovic

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Poklepovic. A scholar is included among the top collaborators of Andrew Poklepovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Poklepovic. Andrew Poklepovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Richard, Nolan A. Wages, Emily Liu, Arnethea L. Sutton, & Andrew Poklepovic. (2025). Understanding the Role of Patient-Reported Outcomes for Decision-Making in Early-Phase Dose-Finding Clinical Trials. Current Oncology. 32(3). 176–176. 1 indexed citations

Fischer, Rachel A., I. Ryan, Joan Levy, et al.. (2024). US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma. Critical Reviews in Oncology/Hematology. 196. 104289–104289. 1 indexed citations

Tsai, Frank, Michael J. Birrer, Jason R. Brown, et al.. (2024). A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.. Journal of Clinical Oncology. 42(16_suppl). 3112–3112. 2 indexed citations

Poklepovic, Andrew, Sarah Gordon, Sejal Kothadia, et al.. (2024). A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors. Anti-Cancer Drugs. 35(5). 450–458. 2 indexed citations

Migden, Michael R., Wanxing Chai‐Ho, Gregory A. Daniels, et al.. (2023). 777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS). SHILAP Revista de lepidopterología. A874–A874. 1 indexed citations

Kasi, Pashtoon Murtaza, Sakti Chakrabarti, Sarah Sawyer, et al.. (2022). BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. BMJ Open. 12(5). e060342–e060342. 9 indexed citations

Olson, Daniel J., Zeynep Eroglu, Bruce Brockstein, et al.. (2021). Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology. 39(24). 2647–2655. 136 indexed citations

Yu, Xiaofei, Wenjie Liu, Shixian Chen, et al.. (2021). Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity. Journal for ImmunoTherapy of Cancer. 9(1). e001595–e001595. 15 indexed citations

Dent, Paul, Laurence Booth, Andrew Poklepovic, et al.. (2021). Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. Biochemical Pharmacology. 190. 114642–114642. 17 indexed citations

10.

Dent, Paul, Laurence Booth, Jane L. Roberts, et al.. (2021). Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43. Aging. 13(13). 17097–17117. 10 indexed citations

11.

Kim, Richard D., Hanna K. Sanoff, Andrew Poklepovic, et al.. (2020). A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 126(15). 3464–3470. 34 indexed citations

12.

Dent, Paul, Laurence Booth, Andrew Poklepovic, Daniel D. Von Hoff, & John F. Hancock. (2020). Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. Cellular Signalling. 68. 109525–109525. 7 indexed citations

13.

Dent, Paul, Laurence Booth, Jane L. Roberts, et al.. (2019). Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. 38(30). 5890–5904. 57 indexed citations

14.

Booth, Laurence, Andrew Poklepovic, & Paul Dent. (2019). Not the comfy chair! Cancer drugs that act against multiple active sites. Expert Opinion on Therapeutic Targets. 23(11). 893–901. 11 indexed citations

15.

Booth, Laurence, Jane L. Roberts, Francesca Avogadri-Connors, et al.. (2018). The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. Cancer Biology & Therapy. 19(3). 239–247. 8 indexed citations

16.

Poklepovic, Andrew, Michael C. Kontos, Maciej Kmieciak, et al.. (2018). Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardio-Oncology. 4(1). 13 indexed citations

17.

Gordon, Sarah, et al.. (2017). Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis. Case Reports in Oncological Medicine. 2017(1). 8095601–8095601. 7 indexed citations

18.

Booth, Laurence, Jane L. Roberts, Mehrad Tavallai, et al.. (2016). [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget. 7(17). 23608–23632. 25 indexed citations

19.

Cruickshanks, Nichola, Hossein A. Hamed, Laurence Booth, et al.. (2013). Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biology & Therapy. 14(10). 982–996. 13 indexed citations

20.

Standaert, Mary L., Gautam Bandyopadhyay, Lamar Galloway, et al.. (1999). Insulin Activates Protein Kinases C-ζ and C-λ by an Autophosphorylation-dependent Mechanism and Stimulates Their Translocation to GLUT4 Vesicles and Other Membrane Fractions in Rat Adipocytes. Journal of Biological Chemistry. 274(36). 25308–25316. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact